We are live on ! Find out more
GLRA

Gerald L. Ray & Associates Portfolio holdings

AUM $802M
1-Year Est. Return 21.01%
This Fund
S&P 500
This Quarter Est. Return
+2.9%
1 Year Est. Return
+21.01%
3 Year Est. Return
+38.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$447M
AUM Growth
–
Cap. Flow
+$452M
Cap. Flow %
101.18%
Top 10 Hldgs %
25.17%
Holding
260
New
260
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.4M
2
CELG
Celgene Corp
CELG
+$16.3M
3
AMGN icon
Amgen
AMGN
+$12.9M
4
LUV icon
Southwest Airlines
LUV
+$12.3M
5
AAPL icon
Apple
AAPL
+$10.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 21.33%
2 Consumer Staples 13.46%
3 Industrials 12.37%
4 Energy 9.97%
5 Technology 9.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVP icon
251
Retractable Technologies
RVP
$20.1M
$22K ﹤0.01%
+15,000
New +$19.2K
TGIC
252
DELISTED
TRIAD GUARANTY INC
TGIC
$7K ﹤0.01%
+16,000
New +$7K
7 8 9 10
11

Similar funds

KRC
Kingdom Ridge Capital White Plains, New York $750M AUM 34.23% 1-Year Est. Return
GS
GAM Systematic Cambridge, United Kingdom $696M AUM 28.4% 1-Year Est. Return
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return
B
BancorpSouth Tupelo, Mississippi $1.01B AUM 4.88% 1-Year Est. Return
JPCCM
J&P (China) Capital Management Hong Kong, China $586M AUM 82.64% 1-Year Est. Return
NBC
Neuberger Berman Canada Toronto, Ontario, Canada $542M AUM 14.17% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
SD
Sumway Development Shanghai, China $427M AUM 43.82% 1-Year Est. Return

Gerald L. Ray & Associates's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Gerald L. Ray & Associates, which disclosed 260 positions worth $447M. Its ten largest holdings account for 25% of the portfolio.

Its largest position is Regeneron Pharmaceuticals: 70,490 shares worth $15.9M.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, followed by Consumer Staples and Industrials.

  • Gerald L. Ray & Associates's largest Q2 2013 buy was Regeneron Pharmaceuticals: 70,490 shares worth $15.9M.
  • Gerald L. Ray & Associates's ten largest holdings make up 25% of its $447M portfolio in Q2 2013.
  • Gerald L. Ray & Associates disclosed 260 positions in Q2 2013, its first 13F filing on record.

Based on Gerald L. Ray & Associates's 13F filing for Q2 2013, filed 1 Aug 2013.